Virtual Seminar: Targeting PIK3CA Mutant Cancers
Zhenghe J. Wang, Ph.D.
Dale H. Cowan and Ruth Goodman Blum Professor of Cancer Research
Department of Genetics and Genome Sciences
Comprehensive Care Center
Case Western Reserve University
Virtual Pioneers in Biomedical Research Seminar: Targeting PIK3CA Mutant Cancers
March 11, 2022
11:00 a.m. to 12:00 p.m.
About this Seminar
PIK3CA is the most frequently mutated oncogene in human cancers. Dr. Wang will present two projects that translate bench discoveries made in his laboratory into clinical trials to treat PIK3CA mutant colorectal cancer patients. The first approach targets glutamine addiction of PIK3CA mutant colorectal cancer, whereas the second approach combines drugs that target epigenetics and PI3K alpha.
Additional Details
This is a free event hosted by the Fralin Biomedical Research Institute and co-sponsored by the institute's Cancer Research Group. The Pioneers in Biomedical Research Seminar Series, which runs annually from September to May, has featured leading biomedical researchers from throughout the country since the program began in 2012. The lectures are also open to all members of the Virginia Tech community including graduate students, undergraduates, faculty, and staff, as well as the public.